| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 01/09/2002 | CN1330661A Procollagen C-proteinase inhibitors |
| 01/09/2002 | CN1330642A N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, irreversible inihibotr of tyrosine kinases |
| 01/09/2002 | CN1330640A Cyclic hydrazine derivatives as TNF-alpha inhibitors |
| 01/09/2002 | CN1330631A Amide derivatives which are useful as cell factor inhibitors |
| 01/09/2002 | CN1330555A Antibodies to truncated VEGF-D and uses thereof |
| 01/09/2002 | CN1330532A Oil-in-water emulsion comprising micronised biologically active agent and appropriate emulsified system |
| 01/09/2002 | CN1329919A Chinese-medicinal wine for treating lumbar intervertebral disk protrusion and hyperosteogeny |
| 01/09/2002 | CN1329916A Chinese medicine for treating rheumatism and rheumatoid diseases |
| 01/09/2002 | CN1329911A Health-care medicinal liquor |
| 01/09/2002 | CN1329902A Medicine 'Toujingbao'-for treating cervical vertebra disease |
| 01/09/2002 | CN1329901A Exterior-applied black plaster for treating bone diseases and its preparing process |
| 01/09/2002 | CN1329898A Medical plaster for treating condensing osteoarthropathy |
| 01/09/2002 | CN1329897A Medicine for preventing and treating hyperosteogeny and its preparing process |
| 01/09/2002 | CN1329896A Medical wine for treating rheumatism, rheumatoid diseases and hyperosteogeny |
| 01/09/2002 | CN1329895A Exterior-applied ointment for treating hyperosteogeny |
| 01/09/2002 | CN1329891A Vascular formation inhibitor |
| 01/08/2002 | US6337411 Muscular disorders |
| 01/08/2002 | US6337350 Inhibitors of formation of advanced glycation endproducts (AGEs) |
| 01/08/2002 | CA2143263C Orally administrable raloxifene formulations |
| 01/03/2002 | WO2002000887A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000727A2 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | WO2002000725A2 G-protein coupled receptor org10 |
| 01/03/2002 | WO2002000691A2 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | WO2002000661A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| 01/03/2002 | WO2002000658A1 Cyclic gmp-specific phosphodiesterase inhibitors |
| 01/03/2002 | WO2002000656A2 Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives |
| 01/03/2002 | WO2002000633A1 Quinolinyl and benzothiazolyl ppar-gamma modulators |
| 01/03/2002 | WO2002000631A2 Benzhydryl derivatives |
| 01/03/2002 | WO2002000611A2 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 01/03/2002 | WO2002000237A1 Therapeutical use of sophora flavescens or sophora subprostrata extracts |
| 01/03/2002 | WO2002000236A1 Extracts from sophora species, method for producing the same and their use |
| 01/03/2002 | WO2002000227A2 Use of lanthanum compounds for the treatment of bone diseases |
| 01/03/2002 | WO2002000210A2 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease |
| 01/03/2002 | WO2002000204A1 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| 01/03/2002 | WO2002000172A2 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | WO2002000167A2 Modified forms of pharmacologically active agents and uses therefor |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001070693A3 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
| 01/03/2002 | WO2001066601A8 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 01/03/2002 | WO2001053344A3 Chondromodulin-i related peptide |
| 01/03/2002 | WO2001045689A3 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 01/03/2002 | WO2001044260A3 Novel purines |
| 01/03/2002 | WO2000061171A9 Uses of mammalian ox2 protein and related reagents |
| 01/03/2002 | US20020002283 Process for preparing growth hormone secretagogues |
| 01/03/2002 | US20020002282 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
| 01/03/2002 | US20020002269 Artemin, a neurotrophic factor |
| 01/03/2002 | US20020002203 Administering an effective amount of a compound selected from aryl(and heterocyclic) ureido and aryl(heterocyclic) carboxamido phenoxyisobutyric acids as inhibitor of glycation and advanced glycation endproducts (AGEs) (protein-aging) |
| 01/03/2002 | US20020002197 Tropisetron, Fabesetron, Ramosetron and other drugs useful for treatment of a non-inflammatory local disease of the musculo-sceletal system, of a local irritation condition of a joint or tendom sheath or local manifestation |
| 01/03/2002 | US20020002191 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 01/03/2002 | US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides |
| 01/03/2002 | US20020002169 Protein kinase inhibitors |
| 01/03/2002 | US20020002165 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 01/03/2002 | US20020002138 For use in treatment of diseases associated with reduced levels of growth hormone |
| 01/03/2002 | US20020002137 Combination of growth hormone secretagogues and antidepressants |
| 01/03/2002 | US20020002135 Pharmaceutical use |
| 01/03/2002 | US20020001640 Method for improving bone modeling and chondrocyte functioning in growing canines |
| 01/03/2002 | US20020001630 Angiogenesis inhibitor |
| 01/03/2002 | DE10028204A1 Verfahren zur Auffindung von medizinisch wertvollen Wirkstoffen Method for identifying medically valuable active ingredients |
| 01/03/2002 | DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin |
| 01/03/2002 | CA2415873A1 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 01/03/2002 | CA2414210A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | CA2414150A1 Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2413201A1 Treatment for cardiovascular disease |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/03/2002 | CA2412610A1 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | CA2412256A1 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | CA2412024A1 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| 01/02/2002 | EP1167366A1 Amine derivatives |
| 01/02/2002 | EP1167363A2 Novel crystalline forms of (3S-trans)-2-(3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl)-4-(trifluoromethyl)-benzoic acid |
| 01/02/2002 | EP1166789A2 Arsenolite containing angiogenesis inhibitor |
| 01/02/2002 | EP1166788A1 Remedies for joint diseases |
| 01/02/2002 | EP1165812A2 Protozoan expression system |
| 01/02/2002 | EP1165790A1 Protease activated receptor 2 variants |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165788A2 Molecules of the immune system |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165781A2 Protease resistant flint analogs |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165602A1 49 human secreted proteins |
| 01/02/2002 | EP1165593A1 ANTISENSE MODULATION OF p38 MITOGEN ACTIVATED PROTEIN KINASE EXPRESSION |
| 01/02/2002 | EP1165566A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 01/02/2002 | EP1165562A1 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 01/02/2002 | EP1165561A1 6-substituted biaryl purine derivatives as potent cyclin/cdk inhibitors and antiproliferative agents |
| 01/02/2002 | EP1165555A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 01/02/2002 | EP1165545A1 Novel compounds |
| 01/02/2002 | EP1165544A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase |
| 01/02/2002 | EP1165533A2 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 01/02/2002 | EP1165516A2 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 01/02/2002 | EP1165514A1 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
| 01/02/2002 | EP1165513A1 Indolinone compounds as kinase inhibitors |
| 01/02/2002 | EP1165506A1 Substituted azetidin-2-ones as cysteine protease inhibitors |
| 01/02/2002 | EP1165502A1 Diaryl derivatives and their use as medicaments |
| 01/02/2002 | EP1165501A1 Alkenyl- and alkynyl-containing metalloprotease inhibitors |
| 01/02/2002 | EP1165500A1 Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| 01/02/2002 | EP1165491A1 Lta4 hydrolase inhibitors |
| 01/02/2002 | EP1165490A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |